Overview
I see patients with chronic liver diseases. I have a clinical and research interest in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Areas of interest include identifying patients at high risk for NAFLD/NASH, developing care pathways to specialty care and creating sustainable multidisciplinary and lifestyle programs for people impacted with NAFLD/NASH.
Current Appointments & Affiliations
Associate Professor of Medicine
·
2023 - Present
Medicine, Gastroenterology,
Medicine
Recent Publications
Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis.
Journal Article Clin Gastroenterol Hepatol · April 10, 2025 BACKGROUND AND AIMS: Liver corrected T1 (cT1), measured with multiparametric magnetic resonance imaging, offers an alternative to liver biopsy to monitor treatment response and liver disease activity. We aimed to perform a systematic evaluation of change i ... Full text Link to item CiteIntegrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial.
Journal Article JAMA · April 23, 2024 IMPORTANCE: Facilitated telemedicine may promote hepatitis C virus elimination by mitigating geographic and temporal barriers. OBJECTIVE: To compare sustained virologic responses for hepatitis C virus among persons with opioid use disorder treated through ... Full text Link to item CiteA Real-World Experience Utilizing the FAST Score to Identify Patients With Nonalcoholic Steatohepatitis Fibrosis
Conference Gastro Hep Advances · January 1, 2024 Background and Aims: We aimed to test the performance of the Fibroscan-aspartate aminotransferase (FAST) score, a noninvasive test, to identify nonalcoholic steatohepatitis (NASH) and significant fibrosis (NASH + ≥F2) in a cohort of patients with a histolo ... Full text CiteRecent Grants
BIO89-100-132 The ENLIGHTEN-Cirrhosis Pro00116849
Clinical TrialPrincipal Investigator · Awarded by 89bio, Inc · 2024 - 2031BIO89-100-131 The ENLIGHTEN-Fibrosis Study Pro00115755. A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.
Clinical TrialPrincipal Investigator · Awarded by 89bio, Inc · 2024 - 2029Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCo Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026View All Grants
Education, Training & Certifications
American University of the Caribbean ·
2005
M.D.